Press Releases

Havn Life Appoints Dennis Staudt

Havn Life Sciences announces appointment of Dennis Staudt to the Board of Directors & Senior Management Reorganization

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),  is pleased to announce that Mr. Dennis Staudt has joined the Company’s Board of Directors. Mr. Staudt has over 35 years’ experience providing sophisticated business advice, having spent most of his career with PricewaterhouseCoopers LLP (“PwC”), including …

Havn Life Sciences announces appointment of Dennis Staudt to the Board of Directors & Senior Management Reorganization Read More »

Havn Life psilocybin application

Havn Life applies for licence to produce and sell psilocybin

The Controlled Drugs and Substances Dealer’s Licence will allow Havn Life to supply naturally-derived psilocybin globally to universities, clinical researchers and companies Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP) (the “Company” or “Havn Life”),  a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive …

Havn Life applies for licence to produce and sell psilocybin Read More »

Havn Life Sciences announces appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, respectively, and the acceleration of Warrants

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), is pleased to announce that Mr. Vic Neufeld has been appointed as the Chairman of the Board of Directors of the Company (the “Board”). Mr. Neufeld brings a wealth of knowledge and experience in the Natural Health Food industry, having …

Havn Life Sciences announces appointments of Vic Neufeld as Chairman and Rick Brar as Vice Chairman of the Board of Directors, respectively, and the acceleration of Warrants Read More »

Havn Life joins UK Psychedelics Working Group with leading international scientists

The working group consists of over 35 academics, researchers and policy specialists from four countries. Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce …

Havn Life joins UK Psychedelics Working Group with leading international scientists Read More »

Havn Life Sciences Inc. Reports Q1 Financial Statements

Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), is pleased to announce Its financial results for the three month period ended July 31, 2020. Please note that all references to currency are in CDN dollars. First Quarter Results for three months ended July 31, 2020 – Financial highlights: …

Havn Life Sciences Inc. Reports Q1 Financial Statements Read More »

Havn Life Sciences submits range of natural health products to Health Canada

Havn Retail, a core pillar of Havn Life continues to reach milestones as the company works towards its launch of a line of retail products Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research and developing standardized psychoactive …

Havn Life Sciences submits range of natural health products to Health Canada Read More »

Havn Life Sciences announces listing approval on the Frankfurt Stock Exchange

Havn Life is now cross-listed and trades on both the CSE & FSE  Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (FSE : 5NP)(the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that it …

Havn Life Sciences announces listing approval on the Frankfurt Stock Exchange Read More »

Havn Life Sciences granted Section 56 exemption to begin scientific work with psilocybin

Havn Life will develop methods for safe, standardized, quality- controlled production of medical compounds extracted from the Psilocybe spp. mushroom September 10, 2020 Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants …

Havn Life Sciences granted Section 56 exemption to begin scientific work with psilocybin Read More »

Psychedelics company Havn Life announces commencement of public trading on the CSE

Havn Life Sciences will trade on the CSE under the Ticker Symbol HAVN September 8, 2020 Vancouver, BC – Havn Life Sciences Inc. (CSE : HAVN) (the “Company” or “Havn Life”), a biotechnology company focused on unlocking human potential using evidence-informed research, and developing standardized psychoactive compounds derived from plants and fungi, is pleased to announce that …

Psychedelics company Havn Life announces commencement of public trading on the CSE Read More »

Havn Life Sciences Announces Completion of Acquisition Transaction

September 4, 2020 Vancouver, BC – Havn Life Sciences Inc. (the “Company” or “Havn Life”), is pleased to announce that it has successfully completed its acquisition of HAVN Research Inc. (“HAVN Research”), acquiring 100% of the outstanding shares of HAVN Research (the “Acquisition Transaction”).  HAVN Research is a biotechnology company engaged in the business of the …

Havn Life Sciences Announces Completion of Acquisition Transaction Read More »

Scroll to Top